Labcorp Launches New DPYD Genotyping Test for Cancer Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: PRnewswire
- Personalized Cancer Treatment: Labcorp has launched an expanded DPYD genotyping test that identifies cancer patients with DPYD variants, enabling the detection of those at risk for severe side effects before treatment, thus supporting safer, personalized care.
- Reducing Chemotherapy Risks: Approximately 9% of patients carry DPYD variants that can impair the metabolism of chemotherapy drugs like 5-FU, increasing the risk of severe toxicity, with an estimated 1,300 deaths annually in the U.S. due to 5-FU toxicity, highlighting the test's significance.
- FDA Warning Update: The FDA has updated the product labeling for 5-FU and capecitabine to include warnings about the risk of severe adverse reactions or death in patients with complete DPD deficiency, emphasizing the importance of DPYD testing prior to treatment to mitigate patient risks.
- Strengthening Leadership in Pharmacogenomics: Labcorp has offered DPYD testing since 2006 and provides pharmacogenomic testing across various specialties, helping healthcare providers tailor therapies using genetic information to reduce preventable harm, further solidifying its leadership in personalized medicine.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 262.750
Low
270.00
Averages
304.45
High
325.00
Current: 262.750
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Labcorp Partners with Alliance for Clinical Trials on Colorectal Cancer Study
- Collaboration Launch: Labcorp Holdings Inc. has partnered with the Alliance for Clinical Trials to initiate a national multicenter clinical trial for newly diagnosed colorectal cancer patients, aiming to enhance participation in genetic testing, particularly for the approximately 10% of cases caused by inherited variants.
- Testing Method Evaluation: The trial will assess whether proactive outreach by healthcare providers can improve first-degree relatives' participation in cascade genetic testing, thereby enhancing communication of genetic risk among families and increasing early diagnosis potential.
- Impact of Multigene Testing: The study will also evaluate the impact of multigene panel testing on patients newly diagnosed with colorectal cancer, aiming to support more effective treatment options through scientific data, ultimately improving patient survival rates and quality of life.
- National Cancer Institute Support: Sponsored by the National Cancer Institute, the trial will leverage Labcorp's national scale and scientific expertise to ensure high-quality genetic testing services at participating sites, further advancing cancer research.
See More
Labcorp Partners with Alliance for Clinical Trials to Enhance Genetic Testing in Colorectal Cancer
- Trial Launch: Labcorp collaborates with the Alliance for Clinical Trials to initiate a national multicenter clinical trial aimed at increasing genetic testing participation among family members of colorectal cancer patients, which is expected to significantly enhance hereditary risk identification.
- Importance of Testing: Approximately 10% of colorectal cancer cases are linked to inherited variants, yet less than one-third of at-risk relatives undergo recommended genetic testing; this trial will assess the impact of proactive outreach by healthcare providers on testing participation.
- Multigene Testing Evaluation: The trial will also evaluate the impact of multigene panel testing on the care of newly diagnosed colorectal cancer patients, aiming to drive the application of genetic testing in cancer management through scientific evidence.
- Support from NCI: Sponsored by the National Cancer Institute, the trial encompasses patients and their relatives nationwide, reflecting Labcorp's ongoing commitment to advancing genetics-based approaches in cancer care.
See More
Labcorp Partners with Alliance for Clinical Trials to Enhance Genetic Testing in Colorectal Cancer
- Genetic Testing Collaboration: Labcorp has partnered with the Alliance for Clinical Trials to conduct a national multicenter clinical trial aimed at increasing participation in genetic testing among family members of colorectal cancer patients, which is expected to enhance hereditary risk identification and improve preventive measures for patients and their families.
- Low Testing Rates: Research indicates that less than one-third of at-risk relatives receive recommended genetic testing, and this trial will assess whether proactive outreach by healthcare providers can improve this rate, thereby enhancing health management for family members.
- Impact of Multigene Testing: The trial will also evaluate the impact of multigene panel testing on the care of newly diagnosed colorectal cancer patients, aiming to support more effective treatment plans through scientific evidence and improve overall patient outcomes.
- Support from National Cancer Institute: Sponsored by the National Cancer Institute, the trial will enroll patients and their relatives nationwide, reflecting Labcorp's ongoing commitment to advancing genetics-based approaches in cancer care and improving patient outcomes through high-impact clinical research.
See More
Labcorp Partners with Alliance for Clinical Trials to Expand Genetic Testing in Colorectal Cancer
- Trial Launch: Labcorp collaborates with the Alliance for Clinical Trials to initiate a multicenter clinical trial for newly diagnosed colorectal cancer patients, aiming to enhance genetic testing rates among at-risk family members, which is expected to significantly improve genetic risk identification.
- Importance of Testing: Approximately 10% of colorectal cancer cases are linked to inherited variants; however, less than one-third of at-risk relatives receive recommended genetic testing, indicating substantial room for improvement in preventive measures.
- Proactive Intervention Strategy: The trial will assess whether proactive outreach by healthcare providers can increase participation rates of first-degree relatives in genetic testing, potentially transforming the current reliance on patients to communicate genetic risks to their families.
- Clinical Research Impact: Sponsored by the National Cancer Institute, the study will enroll patients and relatives nationwide, with findings expected to provide empirical evidence on effectively communicating genetic testing results, thereby enhancing the quality of care for colorectal cancer patients.
See More
Labcorp Launches New DPYD Genotyping Test for Cancer Patients
- Personalized Cancer Treatment: Labcorp has launched an expanded DPYD genotyping test that identifies cancer patients with DPYD variants, enabling the detection of those at risk for severe side effects before treatment, thus supporting safer, personalized care.
- Reducing Chemotherapy Risks: Approximately 9% of patients carry DPYD variants that can impair the metabolism of chemotherapy drugs like 5-FU, increasing the risk of severe toxicity, with an estimated 1,300 deaths annually in the U.S. due to 5-FU toxicity, highlighting the test's significance.
- FDA Warning Update: The FDA has updated the product labeling for 5-FU and capecitabine to include warnings about the risk of severe adverse reactions or death in patients with complete DPD deficiency, emphasizing the importance of DPYD testing prior to treatment to mitigate patient risks.
- Strengthening Leadership in Pharmacogenomics: Labcorp has offered DPYD testing since 2006 and provides pharmacogenomic testing across various specialties, helping healthcare providers tailor therapies using genetic information to reduce preventable harm, further solidifying its leadership in personalized medicine.
See More
Labcorp Launches AI-Powered MyLabcorp App for Enhanced Health Insights
- AI App Launch: Labcorp has introduced the MyLabcorp app, which integrates lab results with AI features to provide users with personalized health information, thereby enhancing the quality of conversations with healthcare providers and boosting user confidence in health management.
- Market Demand Response: A Labcorp survey reveals that 55% of consumers consider AI crucial for understanding healthcare information, with 41% already using AI to interpret lab results, indicating a strong market demand for intelligent health tools, which MyLabcorp directly addresses.
- Technological Integration Advantage: MyLabcorp combines Labcorp's scientific expertise with OpenAI models to help users identify health patterns and understand test results, enhancing users' health management capabilities in a secure environment, further solidifying Labcorp's leadership in innovative healthcare services.
- App Availability: MyLabcorp is now available on the Apple App Store and Google Play Store, with ongoing feature rollouts, reflecting Labcorp's commitment to technology investment aimed at continuously improving user health management experiences through innovation.
See More
Labcorp Partners with Alliance for Clinical Trials on Colorectal Cancer Study
- Collaboration Launch: Labcorp Holdings Inc. has partnered with the Alliance for Clinical Trials to initiate a national multicenter clinical trial for newly diagnosed colorectal cancer patients, aiming to enhance participation in genetic testing, particularly for the approximately 10% of cases caused by inherited variants.
- Testing Method Evaluation: The trial will assess whether proactive outreach by healthcare providers can improve first-degree relatives' participation in cascade genetic testing, thereby enhancing communication of genetic risk among families and increasing early diagnosis potential.
- Impact of Multigene Testing: The study will also evaluate the impact of multigene panel testing on patients newly diagnosed with colorectal cancer, aiming to support more effective treatment options through scientific data, ultimately improving patient survival rates and quality of life.
- National Cancer Institute Support: Sponsored by the National Cancer Institute, the trial will leverage Labcorp's national scale and scientific expertise to ensure high-quality genetic testing services at participating sites, further advancing cancer research.
See More
Labcorp Partners with Alliance for Clinical Trials to Enhance Genetic Testing in Colorectal Cancer
- Trial Launch: Labcorp collaborates with the Alliance for Clinical Trials to initiate a national multicenter clinical trial aimed at increasing genetic testing participation among family members of colorectal cancer patients, which is expected to significantly enhance hereditary risk identification.
- Importance of Testing: Approximately 10% of colorectal cancer cases are linked to inherited variants, yet less than one-third of at-risk relatives undergo recommended genetic testing; this trial will assess the impact of proactive outreach by healthcare providers on testing participation.
- Multigene Testing Evaluation: The trial will also evaluate the impact of multigene panel testing on the care of newly diagnosed colorectal cancer patients, aiming to drive the application of genetic testing in cancer management through scientific evidence.
- Support from NCI: Sponsored by the National Cancer Institute, the trial encompasses patients and their relatives nationwide, reflecting Labcorp's ongoing commitment to advancing genetics-based approaches in cancer care.
See More
Labcorp Partners with Alliance for Clinical Trials to Enhance Genetic Testing in Colorectal Cancer
- Genetic Testing Collaboration: Labcorp has partnered with the Alliance for Clinical Trials to conduct a national multicenter clinical trial aimed at increasing participation in genetic testing among family members of colorectal cancer patients, which is expected to enhance hereditary risk identification and improve preventive measures for patients and their families.
- Low Testing Rates: Research indicates that less than one-third of at-risk relatives receive recommended genetic testing, and this trial will assess whether proactive outreach by healthcare providers can improve this rate, thereby enhancing health management for family members.
- Impact of Multigene Testing: The trial will also evaluate the impact of multigene panel testing on the care of newly diagnosed colorectal cancer patients, aiming to support more effective treatment plans through scientific evidence and improve overall patient outcomes.
- Support from National Cancer Institute: Sponsored by the National Cancer Institute, the trial will enroll patients and their relatives nationwide, reflecting Labcorp's ongoing commitment to advancing genetics-based approaches in cancer care and improving patient outcomes through high-impact clinical research.
See More
Labcorp Partners with Alliance for Clinical Trials to Expand Genetic Testing in Colorectal Cancer
- Trial Launch: Labcorp collaborates with the Alliance for Clinical Trials to initiate a multicenter clinical trial for newly diagnosed colorectal cancer patients, aiming to enhance genetic testing rates among at-risk family members, which is expected to significantly improve genetic risk identification.
- Importance of Testing: Approximately 10% of colorectal cancer cases are linked to inherited variants; however, less than one-third of at-risk relatives receive recommended genetic testing, indicating substantial room for improvement in preventive measures.
- Proactive Intervention Strategy: The trial will assess whether proactive outreach by healthcare providers can increase participation rates of first-degree relatives in genetic testing, potentially transforming the current reliance on patients to communicate genetic risks to their families.
- Clinical Research Impact: Sponsored by the National Cancer Institute, the study will enroll patients and relatives nationwide, with findings expected to provide empirical evidence on effectively communicating genetic testing results, thereby enhancing the quality of care for colorectal cancer patients.
See More
Labcorp Launches New DPYD Genotyping Test for Cancer Patients
- Personalized Cancer Treatment: Labcorp has launched an expanded DPYD genotyping test that identifies cancer patients with DPYD variants, enabling the detection of those at risk for severe side effects before treatment, thus supporting safer, personalized care.
- Reducing Chemotherapy Risks: Approximately 9% of patients carry DPYD variants that can impair the metabolism of chemotherapy drugs like 5-FU, increasing the risk of severe toxicity, with an estimated 1,300 deaths annually in the U.S. due to 5-FU toxicity, highlighting the test's significance.
- FDA Warning Update: The FDA has updated the product labeling for 5-FU and capecitabine to include warnings about the risk of severe adverse reactions or death in patients with complete DPD deficiency, emphasizing the importance of DPYD testing prior to treatment to mitigate patient risks.
- Strengthening Leadership in Pharmacogenomics: Labcorp has offered DPYD testing since 2006 and provides pharmacogenomic testing across various specialties, helping healthcare providers tailor therapies using genetic information to reduce preventable harm, further solidifying its leadership in personalized medicine.
See More
Labcorp Launches AI-Powered MyLabcorp App for Enhanced Health Insights
- AI App Launch: Labcorp has introduced the MyLabcorp app, which integrates lab results with AI features to provide users with personalized health information, thereby enhancing the quality of conversations with healthcare providers and boosting user confidence in health management.
- Market Demand Response: A Labcorp survey reveals that 55% of consumers consider AI crucial for understanding healthcare information, with 41% already using AI to interpret lab results, indicating a strong market demand for intelligent health tools, which MyLabcorp directly addresses.
- Technological Integration Advantage: MyLabcorp combines Labcorp's scientific expertise with OpenAI models to help users identify health patterns and understand test results, enhancing users' health management capabilities in a secure environment, further solidifying Labcorp's leadership in innovative healthcare services.
- App Availability: MyLabcorp is now available on the Apple App Store and Google Play Store, with ongoing feature rollouts, reflecting Labcorp's commitment to technology investment aimed at continuously improving user health management experiences through innovation.
See More
